Home › Focal Segmental Glomerulosclerosis › Michigan › Ann Arbor
Focal Segmental Glomerulosclerosis clinical trials in Ann Arbor, MI
6 studies for Focal Segmental Glomerulosclerosis are looking for participants at sites in and around Ann Arbor (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
RecruitingPhase 2
- University of Michigan Health System - Ann Arbor- Site Number : 8400010, Ann Arbor
Nephrotic Syndrome Study Network
RecruitingObservational study
- CS Mott Children's Hospital, University of Michigan, Ann Arbor
- University of Michigan Medical Center, Ann Arbor
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RecruitingPhase 2
- C.S. Mott Children's Hospital, Ann Arbor
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
RecruitingObservational study
- University of Michigan, Ann Arbor
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
RecruitingPhase 3
- University of Michigan, Ann Arbor
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
RecruitingObservational study
- University of Michigan, Ann Arbor
Focal Segmental Glomerulosclerosis trials in other cities
- Philadelphia, PA9 studies
- Durham, NC8 studies
- New York City, NY7 studies
- Los Angeles, CA6 studies
- Miami, FL6 studies
- Queens, NY6 studies
- Atlanta, GA5 studies
- Houston, TX5 studies
- Kansas City, MO4 studies
- Chicago, IL4 studies
- Cleveland, OH4 studies
- Dallas, TX4 studies
Other studies in Ann Arbor
- Prostate Cancer27 studies
- Cancer (all types)26 studies
- Breast Cancer26 studies
- Non-Small Cell Lung Cancer26 studies
- Lung Cancer23 studies
- Colorectal Cancer23 studies
- Heart Failure22 studies
- Acute Myeloid Leukemia17 studies
- Cardiovascular Disease16 studies
- Pancreatic Cancer14 studies
- Melanoma12 studies
- Kidney Cancer (Renal Cell Carcinoma)12 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.